Lipid-Lowering Agents - South America

South America

In South America, the revenue in the Lipid-Lowering Agents market is estimated to surpass US$221.70m by the year 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2028) of 0.18%, leading to a projected market volume of US$223.30m by 2028.
When compared globally, United States is expected to generate the highest revenue in this market, reaching a staggering US$4,427.00m in 2024.
In South America, the demand for lipid-lowering agents is steadily increasing due to the rising prevalence of cardiovascular diseases.

Key regions: Italy, Japan, France, Brazil, Australia

Market

Region

Region comparison

Currency

Analyst Opinion

The market for Lipid-Lowering Agents in South America has been experiencing significant growth in recent years, with a number of trends and developments contributing to this expansion.

Customer preferences: South American consumers have become increasingly health-conscious in recent years, with a growing awareness of the importance of maintaining healthy cholesterol levels. This has led to a greater demand for Lipid-Lowering Agents, as consumers seek out effective ways to manage their cholesterol and reduce their risk of heart disease.

Trends in the market: One of the key trends driving growth in the Lipid-Lowering Agents market in South America is the increasing availability of generic drugs. As more and more generic Lipid-Lowering Agents become available, consumers are able to access these medications at a lower cost, which has helped to drive demand and increase market penetration.Another trend that is contributing to the growth of the market is the increasing prevalence of hyperlipidemia in South America. As the population ages and lifestyles become increasingly sedentary, rates of hyperlipidemia are expected to continue to rise, which will drive demand for Lipid-Lowering Agents in the coming years.

Local special circumstances: There are a number of local factors that are also contributing to the growth of the Lipid-Lowering Agents market in South America. For example, many countries in the region have implemented government-sponsored programs to improve access to healthcare, which has helped to increase demand for Lipid-Lowering Agents among underserved populations.In addition, there is a growing trend towards self-medication in South America, which has led to an increase in demand for over-the-counter Lipid-Lowering Agents. As consumers become more empowered to take control of their own health, they are increasingly turning to these types of products to manage their cholesterol levels.

Underlying macroeconomic factors: Finally, there are a number of macroeconomic factors that are contributing to the growth of the Lipid-Lowering Agents market in South America. For example, the region's growing middle class has increased demand for healthcare products and services, including Lipid-Lowering Agents.In addition, the region's economic growth has led to increased investment in healthcare infrastructure, which has helped to improve access to Lipid-Lowering Agents and other healthcare products. As these trends continue, it is likely that the Lipid-Lowering Agents market in South America will continue to grow and expand in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.